WALTHAM, Mass.--(BUSINESS WIRE)-- Visterra, Inc. (Visterra) announces that Otsuka Pharmaceutical Co., Ltd. of Japan has completed the acquisition of Visterra for approximately USD 430 million in an all-cash transaction. The acquisition was completed on August 31, 2018. Visterra will operate as a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan.

Otsuka Pharmaceutical Co., Ltd. has issued this announcement in Japan.

About Visterra, Inc.
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Its proprietary Hierotope® platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The platform also includes Fc engineering capabilities for half-life extension, bispecific antibodies and antibody-drug conjugates (ADCs). Visterra's pipeline includes programs targeting IgA nephropathy and other kidney diseases, cancer, chronic pain and infectious diseases. Visterra is funded by investments by Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Global Healthcare Fund, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities.

https://firstwordpharma.com/story/4646903

‍